| pubmed-article:11413522 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11413522 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:11413522 | lifeskim:mentions | umls-concept:C1556084 | lld:lifeskim |
| pubmed-article:11413522 | lifeskim:mentions | umls-concept:C0029925 | lld:lifeskim |
| pubmed-article:11413522 | lifeskim:mentions | umls-concept:C0600558 | lld:lifeskim |
| pubmed-article:11413522 | lifeskim:mentions | umls-concept:C1096776 | lld:lifeskim |
| pubmed-article:11413522 | lifeskim:mentions | umls-concept:C1519810 | lld:lifeskim |
| pubmed-article:11413522 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:11413522 | pubmed:dateCreated | 2001-6-19 | lld:pubmed |
| pubmed-article:11413522 | pubmed:abstractText | Initial debulking surgery followed by chemotherapy is the current treatment for International Federation of Gynecology and Obstetrics Stage IIIC/IV ovarian carcinoma but has a limited efficacy when optimal cytoreduction is not achieved at the end of the surgical procedure. An alternative treatment for these patients could be neoadjuvant chemotherapy. The purpose of this retrospective study was to report the results of neoadjuvant chemotherapy in operable patients (no medical contraindication to surgery) presenting with primary unresectable tumors. | lld:pubmed |
| pubmed-article:11413522 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11413522 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11413522 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:11413522 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11413522 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:11413522 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:11413522 | pubmed:author | pubmed-author:QuerleuDD | lld:pubmed |
| pubmed-article:11413522 | pubmed:author | pubmed-author:DargentDD | lld:pubmed |
| pubmed-article:11413522 | pubmed:author | pubmed-author:MoricePP | lld:pubmed |
| pubmed-article:11413522 | pubmed:author | pubmed-author:DauplatJJ | lld:pubmed |
| pubmed-article:11413522 | pubmed:author | pubmed-author:CastaigneDD | lld:pubmed |
| pubmed-article:11413522 | pubmed:author | pubmed-author:LeblancEE | lld:pubmed |
| pubmed-article:11413522 | pubmed:author | pubmed-author:SchererCC | lld:pubmed |
| pubmed-article:11413522 | pubmed:author | pubmed-author:LhomméCC | lld:pubmed |
| pubmed-article:11413522 | pubmed:author | pubmed-author:TigaudJ DJD | lld:pubmed |
| pubmed-article:11413522 | pubmed:author | pubmed-author:MathevetPP | lld:pubmed |
| pubmed-article:11413522 | pubmed:author | pubmed-author:CloughKK | lld:pubmed |
| pubmed-article:11413522 | pubmed:author | pubmed-author:BenchaibMM | lld:pubmed |
| pubmed-article:11413522 | pubmed:author | pubmed-author:AnsquerYY | lld:pubmed |
| pubmed-article:11413522 | pubmed:author | pubmed-author:FourmeEE | lld:pubmed |
| pubmed-article:11413522 | pubmed:copyrightInfo | Copyright 2001 American Cancer Society. | lld:pubmed |
| pubmed-article:11413522 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11413522 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:11413522 | pubmed:volume | 91 | lld:pubmed |
| pubmed-article:11413522 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11413522 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11413522 | pubmed:pagination | 2329-34 | lld:pubmed |
| pubmed-article:11413522 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:meshHeading | pubmed-meshheading:11413522... | lld:pubmed |
| pubmed-article:11413522 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11413522 | pubmed:articleTitle | Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. | lld:pubmed |
| pubmed-article:11413522 | pubmed:affiliation | Edouard Herriot Hospital, Lyon Cedex, France. yan.ansquer@wanadoo.fr | lld:pubmed |
| pubmed-article:11413522 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11413522 | pubmed:publicationType | Evaluation Studies | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11413522 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11413522 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11413522 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11413522 | lld:pubmed |
